Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma with high heterogeneity [1]. The standard first-line treatment regimen is R-CHOP (rituximab-cyclophosphamide + adriamycin + vincristine + prednisone), with 5-year survival rates of 60%–70% [2], but more than 30% of patients will still develop relapsed/refractory DLBCL due to resistance to targeted and chemotherapeutic agents, resulting in poor prognosis [1,2]. Scholars have investigated the mechanism of resistance to rituximab, but a conclusive understanding is yet to be established. Anti-CD20 antibodies, drug resistance, genetic alterations, and molecular mechanisms are the main topics of this chapter.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
